{"id":672439,"date":"2023-10-16T18:46:01","date_gmt":"2023-10-16T18:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=672439"},"modified":"2023-10-16T18:46:01","modified_gmt":"2023-10-16T18:46:01","slug":"ischemic-stroke-market-on-the-verge-of-extraordinary-growth-during-the-forecast-period-202332-boehringer-ingelheim-bayer-penumbra-pfizer-astrazeneca-daiichi-sankyo-biogen-merck-novartis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ischemic-stroke-market-on-the-verge-of-extraordinary-growth-during-the-forecast-period-202332-boehringer-ingelheim-bayer-penumbra-pfizer-astrazeneca-daiichi-sankyo-biogen-merck-novartis_672439.html","title":{"rendered":"Ischemic Stroke Market on the Verge of Extraordinary Growth During the Forecast Period (2023-32) | Boehringer Ingelheim, Bayer, Penumbra, Pfizer, AstraZeneca, Daiichi Sankyo, Biogen, Merck, Novartis"},"content":{"rendered":"
\n
\"Ischemic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Ischemic Stroke Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Ischemic Stroke and the launch of new therapies in the market.<\/div>\n

DelveInsight’s “Ischemic Stroke Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ischemic Stroke market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Ischemic Stroke drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Ischemic Stroke treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Ischemic Stroke: An Overview<\/strong><\/p>\n

Ischemic stroke, sometimes called a brain attack, occurs when something blocks blood supply to part of the brain or when a blood vessel in the brain bursts. In either case, parts of the brain become damaged or die. A stroke can cause lasting brain damage, long-term disability, or even death. The blockage caused by this stroke reduces the blood flow and oxygen to the brain, leading to damage or death of brain cells. Approximately 87 percent of all strokes are ischemic strokes.<\/p>\n

The main treatments aiming to break up or remove clots from the brain are usually only available within a few hours of a stroke. The two ways of treating clots in the brain are Thrombolysis (clot-busting medication – r-tPA, known as alteplase) and Thrombectomy (mechanical clot removal). Other medications are given to prevent and dissolve blood clots, reduce blood pressure, and reduce cholesterol levels.<\/p>\n

\"\"<\/p>\n

Ischemic Stroke Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Ischemic Stroke pipeline therapies<\/strong>. It also thoroughly assesses the Ischemic Stroke market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.<\/p>\n

The report gives complete details of the market trend for each marketed Ischemic Stroke drug<\/strong> and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.<\/p>\n

Ischemic Stroke Epidemiology Assessment <\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted Ischemic Stroke epidemiology trends<\/strong> in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Ischemic Stroke epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. <\/p>\n

Ischemic Stroke Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Ischemic Stroke market<\/strong> or expected to be launched during the study period. The analysis covers the Ischemic Stroke market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Ischemic Stroke drugs based on their sale and market share.<\/p>\n

The report also covers the Ischemic Stroke pipeline development activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key Ischemic Stroke companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Learn How the Ischemic Stroke Market Will Evolve and Grow by 2032 @ <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/ischemic-stroke-market<\/strong><\/a><\/p>\n

Ischemic Stroke Therapeutics Analysis<\/strong><\/p>\n

Several major pharma and biotech companies are developing therapies for Ischemic Stroke. Currently, ZZ Biotech<\/strong> is leading the therapeutics market with its Ischemic Stroke drug candidates in the most advanced stage of clinical development.<\/p>\n

Ischemic Stroke Companies Actively Working in the Therapeutics Market Include<\/strong><\/p>\n

Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Daiichi Sankyo Company, Limited, Johnson & Johnson, Biogen Inc., Merck & Co., Inc., Novartis AG, Sanofi S.A, Eli Lilly and Company, Stryker Corporation, Penumbra, Inc., Medtronic, Inc., Boston Scientific Corporation, and many others.<\/p>\n

Emerging and Marketed Ischemic Stroke Therapies Covered in the Report Include:<\/strong><\/p>\n